Inhibikase Therapeutics I... (IKT)
NASDAQ: IKT
· Real-Time Price · USD
1.54
-0.02 (-1.28%)
At close: Sep 18, 2025, 2:02 PM
-1.28% (1D)
| Bid | 1.13 |
| Market Cap | 115.13M |
| Revenue (ttm) | 26.27K |
| Net Income (ttm) | -41.5M |
| EPS (ttm) | -0.04 |
| PE Ratio (ttm) | -38.62 |
| Forward PE | -2.74 |
| Analyst | Hold |
| Dividends | n/a |
| Ask | 1.99 |
| Volume | 105,392 |
| Avg. Volume (20D) | 239,438 |
| Open | 1.58 |
| Previous Close | 1.56 |
| Day's Range | 1.54 - 1.60 |
| 52-Week Range | 1.12 - 4.20 |
| Beta | 0.92 |
| Ex-Dividend Date | n/a |
Analyst Forecast
According to 0 analyst ratings, the average rating for IKT stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts10 months ago
-13.14%
Inhibikase Therapeutics shares are trading lower. ...
Unlock content with
Pro Subscription
10 months ago
+3.6%
Inhibikase Therapeutics shares are trading higher after Jefferies initiated coverage on the stock with a Buy rating and announced an $8 price target.
